维普期刊资源整合服务平台（V6.5）

177篇 您的检索式：作者名="TANNOCK IF"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	Bone metastases:pathophysiology and management policy显示文摘	Nielsen OS Munro AJ Tannock IF		0，，03：	1
2	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer 显示文摘	Tannock IF de Wit R Berry WR	2004	N Engl J Med2004，351，15：	1
3	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	Tannock IF deWit R Berry WJ	2004	N Engl J Med2004，351，：	1
4	Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma显示文摘	Ma BBY Tannock IF Pond GR	2002	Cancer2002，95，12：	1
5	Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a sys- tematic review of randomized trials 显示文摘	Niraula S Le LW Tannock IF	2013	J Clin Oncol2013，31，16：	1
6	Potential drug interactions and duplicate prescriptions among cancer patients显示文摘	Riechelmann RP Tannock IF Wang L	2007	Journal of the National Cancer Institute2007，99，8：	1
7	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	Tannock IF de Wit R Berry WR	2004	N Engl J Med2004，351，：	1
8	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	Tannock IF de Wit R Berry WR	2004	N Engl J Med2004，351，15：	1
9	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival显示文摘	Armstrong AJ Tannock IF de WitR	2010	Eur J Cancer2010，46，3：	1
10	Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions显示文摘	Tannock IF	1992	Cancer Res1992，52，16：	1
11	Phase II trial of mirtazapine for cancer-related cachexia and anorexia显示文摘	Riechelmann RP Burman D Tannock IF	2010	Am J Hosp Palliat Care2010，27，2：	1
12	Chemother- apy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian ran- domized trial with palliative end points显示文摘	TANNOCK IF OSOBA D STOCKLER MR	1996	J Clin Oncol1996，14，6：	1
13	Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:Recommendations of the Prostate Cancer Clinical Trials Working Group显示文摘	SCHER HI HALABI S TANNOCK IF	2008	J Clin Oncol2008，26，：	1
14	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer显示文摘	TANNOCK IF DE WIT R BERRY WR	2004	N Engl J Med2004，351，15：	1
15	Doeetaxel plus Prednisone or Mitoxantrone lus Prednisone for Advanced Pros- tate Cancer显示文摘	TANNOCK IF WIT R BERRY WR et a	2004	N Engl J Meal2004，351，15：	1
16	Cytostatic potential of novel agents that inhibit the regulation of intracellular pH显示文摘	Wong P Kleemann HW Tannock IF	2002	Br J Cancer2002，87，2：	1
17	Docetaxel plus prednisone or mit oxantrone plus prednisone for advanced prostate cancer显示文摘	TANNOCK IF DEW IT R BERRY WJ	2004	N Engl J Med2004，351，：	1
18	Randomized phase Ⅲ trial comparin g the new potent and selective third-generation aromatase inhibitor vorozole wi th megestrol acetate in postmenopausal advanced breast cancer patients显示文摘	Goss PE Winer EP Tannock IF	1999	J C lin Oncol1999，17，1：	1
19	Gemcitabine: a promising new agent in the treatment of advanced urotheli- al cancer显示文摘	Moore MJ Tannock IF Ernst DS	1997	J Clin Oncol1997，15，12：	1
20	Chemotherapy with gemcitabine containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma显示文摘	Ma BB Tannock IF Pond GR	2002	Cancer2002，95，12：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示